Español 
English
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Artículos Relacionados
-
UDIBI
Fecha de publicación: Marzo 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio Ver más
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). VER MÁS
-
UDIBI
Fecha de publicación: 20 Septiembre 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable...
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. VER MÁS
-
UDIBI
Fecha de publicación: 16 mayo de 2019 Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract Transferon®) Ver...
-
UDIBI
Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract (Transferon®). VER MÁS
-
UDIBI
Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine. VER MÁS
